Generic Name and Formulations:
Diclofenac sodium 3%; gel; contains benzyl alcohol.
Indications for SOLARAZE:
Use lowest effective dose for shortest duration. Apply to lesions twice daily for 60–90 days.
Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. History of ulcer disease and/or GI bleeding. Severe renal or hepatic impairment. Avoid sun and UV light. Aspirin allergy. Asthma. Avoid eyes, and open skin wounds, infections, or exfoliative dermatitis. Elderly. Labor & delivery. Pregnancy (Cat.B); avoid in 3rd trimester. Nursing mothers: not recommended.
Increased risk of GI events with concomitant aspirin or oral NSAIDs. Concomitant other topical medications or products (eg, sunscreens, cosmetics): not studied.
Pruritus, rash, contact dermatitis, dry skin, exfoliation, local pain, paresthesia; cardiovascular thrombotic events, edema, photosensitivity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML